Daiichi Sankyo Europe: Primary endpoint met in the CLEAR Outcomes Trial of bempedoic acid showing statistically significant relative risk reduction in major adverse CV events

Successful topline results from the CLEAR Outcomes Trial demonstrate that bempedoic acid, marketed as NILEMDO? in Europe, reduces the risk of serious cardiovascular (CV) events in patients with

Related Keywords

Switzerland ,London ,City Of ,United Kingdom ,Turkey ,Kausik Ray ,Wolfgang Schiessl ,Stefan Seyfried ,Daiichi Sankyo ,Daiichi Sankyo Europe ,Daiichi Sankyo Europe Gmb ,Esperion Therapeutics Inc ,Professor Of Public Health ,Sustainable Development Of Society ,Affairs Specialty Medicines ,Innovative Global Healthcare Company ,European Society Of Cardiology ,European Medicines Agency ,European Atherosclerosis Society ,Sankyo Europe ,Cholesterol Lowering ,Inhibiting Regimen ,Outcomes Trial ,Professor Kausik Ray ,Public Health ,Honorary Consultant Cardiologist ,Deputy Director ,Imperial Clinical Trials Unit ,Imperial College ,European Economic Area ,Marketing Authorisation Holder ,Global Healthcare Company Contributing ,Sustainable Development ,Task Force ,European Society ,Product Information ,Human Medicinal ,Sankyo Europe Gmbh ,Communication Lead ,Specialty Medicines ,Daiichi ,Sankyo ,Europe ,Primary ,Ndpoint ,Clear ,Outcomes ,Trial ,Bempedoic ,Acid ,Showing ,Statistically ,Significant ,Relative ,Risk ,Reduction ,Major ,Madverse ,Events ,